DOCSLIB.ORG

Summary of Product Characteristics

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Summary of Product Characteristics common-spc P. 1 of 9 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT <invented name> 100 mg, soft capsule <invented name> 200 mg, soft capsule 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 soft capsule contains: <invented name> 100 mg: Progesterone (micronised) 100 mg <invented name> 200 mg: Progesterone (micronised) 200 mg Excipient with known effect: Soybean lecithin For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Capsule, soft <invented name> 100 mg: Round, slightly yellow soft capsule, containing whitish oily suspension. <invented name> 200 mg: Ovoid, slightly yellow soft capsule, containing whitish oily suspension. Size of the capsule: 100 mg: round 5 200 mg: oval 10 4. CLINICAL PARTICULARS 4.1 Therapeutic indications <invented name> is indicated in adults. Cycle disorders due to progesterone insufficiency, particularly menstrual irregularities, - Adjunctive use in hormone replacement therapy (HRT) with an estrogen in postmenopausal women with an intact uterus. 4.2 Posology and method of administration Posology common-spc P. 2 of 9 The recommended dose is as follows, according to the indication: In luteal failure (irregular periods): The treatment should be taken for 10 days per cycle, usually from the 17th to 26th day inclusive. The average dosage is 200 to 300 mg of progesterone per day, taken as 1 or 2 divided doses, i.e. 200 mg in the evening at bedtime plus 100 mg in the morning if required. In the treatment of menopause: oestrogen-only therapy is not recommended on its own in menopausal women with an intact uterus. A single intake of 200 mg progesterone at bedtime has to be added at least 12 to 14 days per month, i.e. in the last 2 weeks of each treatment sequence, followed by approximately one week without any replacement therapy and during which withdrawal bleeding may occur. Paediatric population There is no relevant use of <invented name> in the paediatric population. Method of administration This product is intended for oral use only. The medicinal product should not be taken with food, preferably in the evening at bedtime. The second intake should be in the morning. 4.3 Contraindications This medicinal product must not be used in the following situations: Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Undiagnosed genital bleeding Severe liver dysfunction Liver tumours Suspected or confirmed breast or genital organ neoplasia Thromboembolic diseases, active or in the history Cerebral haemorrhage Porphyria In case of a contraindication related with estrogens when <invented name> is use for HRT in conjunction with an estrogen (see summaries of product characteristics of the particular estrogen-containing medicinal product). 4.4 Special warnings and precautions for use Under the recommended conditions for use, this treatment is NOT A CONTRACEPTIVE. If the treatment sequence is started too early in the month, particularly before the 15th day of the cycle, the cycle may be shortened or bleeding may occur. common-spc P. 3 of 9 Patients must be monitored closely if they have a history of venous thrombosis. If uterine bleeding is present, do not prescribe before establishing a cause, particularly with endometrial investigations. Because of the metabolic risks and risks of thromboembolism which cannot be entirely excluded, administration should be discontinued in the event of: . Occular disorders such as reduced vision, diplopia and retinal vascular lesions; . Venous thromboembolic or thrombotic events, regardless of location; . Severe headaches. If the patient develops amenorrhoea during treatment, ensure that she is not pregnant. Medical examination/follow-up Before initiating or reinstituting HRT, a complete personal and family medical history should be taken. Physical (including pelvic and breast) examination should be guided by this and by the contraindications and warnings for use. During treatment, periodic check-ups are recommended of a frequency and nature adapted to the individual woman. Women should be advised what changes in their breasts should be reported to their doctor or nurse. Investigations, including appropriate imaging tools, e.g. mammography, should be carried out in accordance with currently accepted screening practices, modified to the clinical needs of the individual. Endometrial hyperplasia In women with still intact endometrium, regular period-like withdrawal bleeding may occur early on in the treatment, which decreases or stops altogether with increasing atrophy of the endometrium in the course of long-term treatment. In the absence of this withdrawal bleeding, endometrial hyperplasia should be excluded by suitable measures. Breakthrough bleeding and spotting may occur during the first few months of the treatment. If break-through bleeding or spotting appears after some time on therapy, or continues after treatment has been discontinued, the reason should be investigated, which may include endometrial biopsy to exclude endometrial malignancy. The risks of combined use of estrogens and progestogens for postmenopausal hormone therapy are described in detail in the summaries of product characteristics of the particular estrogen- containing medicinal products. <invented name> contains soybean lecithin <invented name> contains soybean lecithin and may cause hypersensitivity reactions (urticaria and anaphylactic shock). If a patient is allergic to peanut or soya, the patient should not use this medicinal product (see section 4.3). 4.5 Interaction with other medicinal products and other forms of interaction Drugs known to induce the hepatic CYP450-3A4 such as barbiturates, anti-epileptic agents (phenytoin, carbamazepine), rifampicin, phenylbutazone, spironolactone, griseofulvin, some common-spc P. 4 of 9 antibiotics (ampicillin, tetracyclines) and also herbal products containing St. John’s wort (Hypericum perforatum) may increase the elimination of progesterone. Ketoconazole and other inhibitors of CYP450-3A4 may increase bioavailability of progesterone. Progesterone may affect the results of laboratory tests of hepatic and/or endocrine functions. Progestogens may decrease glucose tolerance and thus, may increase insulin resistance or resistance to any other antidiabetic agents used in patients with diabetes mellitus. 4.6 Fertility, pregnancy and lactation Pregnancy A large amount of data on pregnant women indicate no malformative nor feto/neonatal toxicity of progesterone. Breastfeeding There is insufficient information on the excretion of progesterone/metabolites in human milk. Secretion of progesterone into breast milk has not been studied in detail. <invented name> should not be used during breastfeeding. Fertility As this medicinal product is indicated to support luteal failure in subfertile or infertile women, there is not deleterious known effect on fertility. 4.7 Effects on ability to drive and use machines Drivers and machine operators in particular are alerted to the risks of drowsiness and/or dizziness associated with oral use of this medicinal product. These problems can be avoided by taking the capsules at bedtime. 4.8 Undesirable effects The following adverse reactions have been seen by oral route of administration: Rare System organ Common Uncommon Very rare 1/10000; class 1/100; <1/10 1/1000; ≤1/100 ≤1/10000 ≤1/1000 Menstruation Mastodynia Reproductive irregular system and Amenorrhoea breast disorders Metrorrhagia Headaches Drowsiness Depression Nervous system Fleeting dizzy disorders sensations common-spc P. 5 of 9 Vomiting Nausea Gastrointestinal Diarrhoea disorders Constipation Hepatobiliary Cholestatic disorders jaundice Immune system Anaphylactoid Urticaria disorders reactions Skin and Pruritus Chloasma subcutaneous Acne tissue disorders Drowsiness and/or fleeting dizzy sensations are seen particularly with concomitant hypoestrogenism. These effects disappear immediately without compromising the benefit of treatment when doses are reduced or estrogenism is increased. If the treatment sequence is started too early in the month, particularly before the 15th day of the cycle, the cycle may be shortened or intercurrent bleeding may occur. Changes in periods, amenorrhoea or intercurrent bleeding have been observed and associated with the use of progesterone in general. Other adverse reactions have been reported in association with estrogen/progestogen treatment used as hormone replacement therapy in postmenopausal women: - Estrogen-dependent benign or malignant tumour, e.g. endometrial carcinoma. - Venous thromboembolisms, i.e. thrombosis of the deep leg or pelvic veins as well as pulmonary embolism occur more often in users of hormone replacement therapy than in non- users. - Myocardial infarction and stroke. - Gall bladder disorders. - Skin and subcutaneous tissue disorders: chloasma, erythema multiforme, erythema nodosum, and vascular purpura. - Probable dementia. Detailed information on the side effects of combined use of oestrogens and gestagens for postmenopausal hormone therapy are described in the summaries of product characteristics for the particular estrogen-containing medicinal products. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V. common-spc P. 6 of 9
Load more

Recommended publications
  • COMMENTARY Possible New Mechanism of Cortisol Action In
    211 COMMENTARY Possible new mechanism of cortisol action in female reproductive organs: physiological implications of the free hormone hypothesis C Yding Andersen Laboratory of Reproductive Biology, Section 5712, University Hospital of Copenhagen, DK-2100 Copenhagen, Denmark (Requests for offprints should be addressed to C Yding Andersen; Email: [email protected]) Abstract The so-called free hormone hypothesis predicts that the cortisol to cortisone, while 11-HSD type 1 reverses this biological activity of a given steroid correlates with the free reaction. As a result, a high concentration of cortisol protein-unbound concentration rather than with the total available for biological action is present in the preovulatory concentration (i.e. free plus protein-bound). Cortisol is a follicle just prior to ovulation and it has been suggested that glucocorticoid with many diverse functions and the free cortisol may function to reduce the inflammatory-like hormone hypothesis seems to apply well to the observed reactions occurring in connection with ovulation. effects of cortisol. The ovaries express glucocorticoid This paper suggests (1) that the function of the oviduct receptors and are affected by cortisol, but lack the neces- is also affected by the high levels of free cortisol released in sary enzymes for cortisol synthesis. Ovarian follicles modu- preovulatory follicular fluid at ovulation and (2) that late the biological activity of cortisol by (1) follicular formation and function of the corpus luteum benefits from production of especially progesterone and 17-hydroxy- a high local concentration of free cortisol, whereas the progesterone which, within the follicle, reach levels that surrounding developing follicles may experience negative displace cortisol from its binding proteins, in particular, effects.
    [Show full text]
  • Increased and Mistimed Sex Hormone Production in Night Shift Workers
    Published OnlineFirst March 3, 2015; DOI: 10.1158/1055-9965.EPI-14-1271 Research Article Cancer Epidemiology, Biomarkers Increased and Mistimed Sex Hormone Production & Prevention in Night Shift Workers Kyriaki Papantoniou1,2,3,4, Oscar J. Pozo2, Ana Espinosa1,2,3,4, Josep Marcos2,3, Gemma Castano-Vinyals~ 1,2,3,4, Xavier Basagana~ 1,2,3,4, Elena Juanola Pages 5, Joan Mirabent6,7, Jordi Martín8, Patricia Such Faro9, Amparo Gasco Aparici10, Benita Middleton11, Debra J. Skene11, and Manolis Kogevinas1,2,3,4,12 Abstract Background: Night shift work has been associated with Results: Night workers had higher levels of total progestagens an increased risk for breast and prostate cancer. The effect [geometric mean ratio (GMR) 1.65; 95% confidence intervals of circadian disruption on sex steroid production is a pos- (CI), 1.17–2.32] and androgens (GMR: 1.44; 95% CI, 1.03–2.00), sible underlying mechanism, underinvestigated in hum- compared with day workers, after adjusting for potential con- ans. We have assessed daily rhythms of sex hormones founders. The increased sex hormone levels among night and melatonin in night and day shift workers of both shift workers were not related to the observed suppression of sexes. 6-sulfatoxymelatonin. Peak time of androgens was significantly Methods: We recruited 75 night and 42 day workers, ages later among night workers, compared with day workers (testos- 22 to 64 years, in different working settings. Participants terone: 12:14 hours; 10:06-14:48 vs. 08:35 hours; 06:52-10:46). collected urine samples from all voids over 24 hours on a Conclusions: We found increased levels of progestagens and working day.
    [Show full text]
  • Part I Biopharmaceuticals
    1 Part I Biopharmaceuticals Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 3 1 Analogs and Antagonists of Male Sex Hormones Robert W. Brueggemeier The Ohio State University, Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Columbus, Ohio 43210, USA 1Introduction6 2 Historical 6 3 Endogenous Male Sex Hormones 7 3.1 Occurrence and Physiological Roles 7 3.2 Biosynthesis 8 3.3 Absorption and Distribution 12 3.4 Metabolism 13 3.4.1 Reductive Metabolism 14 3.4.2 Oxidative Metabolism 17 3.5 Mechanism of Action 19 4 Synthetic Androgens 24 4.1 Current Drugs on the Market 24 4.2 Therapeutic Uses and Bioassays 25 4.3 Structure–Activity Relationships for Steroidal Androgens 26 4.3.1 Early Modifications 26 4.3.2 Methylated Derivatives 26 4.3.3 Ester Derivatives 27 4.3.4 Halo Derivatives 27 4.3.5 Other Androgen Derivatives 28 4.3.6 Summary of Structure–Activity Relationships of Steroidal Androgens 28 4.4 Nonsteroidal Androgens, Selective Androgen Receptor Modulators (SARMs) 30 4.5 Absorption, Distribution, and Metabolism 31 4.6 Toxicities 32 Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 4 Analogs and Antagonists of Male Sex Hormones 5 Anabolic Agents 32 5.1 Current Drugs on the Market 32 5.2 Therapeutic Uses and Bioassays
    [Show full text]
  • St. John's Wort 2018
    ONLINE SERIES MONOGRAPHS The Scientific Foundation for Herbal Medicinal Products Hyperici herba St. John's Wort 2018 www.escop.com The Scientific Foundation for Herbal Medicinal Products HYPERICI HERBA St. John's Wort 2018 ESCOP Monographs were first published in loose-leaf form progressively from 1996 to 1999 as Fascicules 1-6, each of 10 monographs © ESCOP 1996, 1997, 1999 Second Edition, completely revised and expanded © ESCOP 2003 Second Edition, Supplement 2009 © ESCOP 2009 ONLINE SERIES ISBN 978-1-901964-61-5 Hyperici herba - St. John's Wort © ESCOP 2018 Published by the European Scientific Cooperative on Phytotherapy (ESCOP) Notaries House, Chapel Street, Exeter EX1 1EZ, United Kingdom www.escop.com All rights reserved Except for the purposes of private study, research, criticism or review no part of this text may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, without the written permission of the publisher. Important Note: Medical knowledge is ever-changing. As new research and clinical experience broaden our knowledge, changes in treatment may be required. In their efforts to provide information on the efficacy and safety of herbal drugs and herbal preparations, presented as a substantial overview together with summaries of relevant data, the authors of the material herein have consulted comprehensive sources believed to be reliable. However, in view of the possibility of human error by the authors or publisher of the work herein, or changes in medical knowledge, neither the authors nor the publisher, nor any other party involved in the preparation of this work, warrants that the information contained herein is in every respect accurate or complete, and they are not responsible for any errors or omissions or for results obtained by the use of such information.
    [Show full text]
  • Mindy Goldman, MD Clinical Professor Dept
    Managing Menopause Medically and Naturally Mindy Goldman, MD Clinical Professor Dept. of Ob/Gyn and Reproductive Sciences Director, Women’s Cancer Care Program, UCSF Breast Care Center and Women’s Health University of California, San Francisco I have nothing to disclose –Mindy Goldman, MD CASE STUDY 50 yr. old G2P2 peri-menopausal woman presents with complaints of significant night sweats interfering with her ability to sleep. She has mild hot flashes during the day. She has never had a bone mineral density test but her mother had a hip fracture at age 62 due to osteoporosis. Her 46 yr. old sister was diagnosed with breast cancer at age 43, treated with lumpectomy and radiation and currently is doing well. There is no other family history of cancer. Questions 1. Would you offer her MHT? 2. If yes, how long would you continue it? 3. If no, what would you offer for alternative treatments? 4. Would your treatment differ if you knew she had underlying heart disease? Is it safe? How long can I take it? What about Mymy Bones?bones? Will it protect my heart? MHT - 2015 What about my brain? Will I get breast cancer? What about my hot flashes? Menopausal Symptoms Hot flashes Night sweats Sleep disturbances Vaginal dryness/Sexual dysfunction Mood disturbances How to Treat Menopausal Symptoms Hormone therapy Alternatives to hormones Complementary and Integrative Techniques Prior to Women’s Health Initiative Hormone therapy primary treatment of menopausal hot flashes Few women would continue hormones past one year By 1990’s well known
    [Show full text]
  • PROMETRIUM® (Progesterone, USP) Capsules 200 Mg WARNING
    PROMETRIUM® (progesterone, USP) Capsules 100 mg Capsules 200 mg WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER AND PROBABLE DEMENTIA FOR ESTROGEN PLUS PROGESTIN THERAPY Cardiovascular Disorders and Probable Dementia Estrogens plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia. (See CLINICAL STUDIES and WARNINGS, Cardiovascular disorders and Probable dementia.) The Women's Health Initiative (WHI) estrogen plus progestin substudy reported increased risks of deep vein thrombosis, pulmonary embolism, stroke and myocardial infarction in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg] combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo. (See CLINICAL STUDIES and WARNINGS, Cardiovascular disorders.) The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women. (See CLINICAL STUDIES and WARNINGS, Probable dementia and PRECAUTIONS, Geriatric Use.) Breast Cancer The WHI estrogen plus progestin substudy also demonstrated an increased risk of invasive breast cancer. (See CLINICAL STUDIES and WARNINGS, Malignant neoplasms, Breast Cancer.) In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and MPA, and other combinations and dosage forms of estrogens and progestins. Progestins with estrogens should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.
    [Show full text]
  • Assessment Report on Hypericum Perforatum L., Herba
    European Medicines Agency Evaluation of Medicines for Human Use London, 12 November 2009 Doc. Ref.: EMA/HMPC/101303/2008 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) ASSESSMENT REPORT ON HYPERICUM PERFORATUM L., HERBA 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 51 E-mail: [email protected] http://www.emea.europa.eu © European Medicines Agency, 2009. Reproduction is authorised provided the source is acknowledged TABLE OF CONTENTS I. REGULATORY STATUS OVERVIEW...................................................................................4 II. ASSESSMENT REPORT............................................................................................................5 II.1 INTRODUCTION..........................................................................................................................6 II.1.1 Description of the herbal substance(s), herbal preparation(s) or combinations thereof 6 II.1.1.1 Herbal substance:........................................................................................................ 6 II.1.1.2 Herbal preparation(s): ................................................................................................ 7 II.1.1.3 Combinations of herbal substance(s) and/or herbal preparation(s)........................... 9 Not applicable. ................................................................................................................................9 II.1.1.4 Vitamin(s) ...................................................................................................................
    [Show full text]
  • Oral Contraceptives and Endocrine Changes* 0
    Bull. Org. mond. Sante 1972, 46, 443-450 Bull. Wid HIth Org. Oral contraceptives and endocrine changes* 0. J. LUCIS1 & R. LUCIS In groups of women taking oral contraceptives and in control groups ofwomen, the serum levels ofcortisol, protein-bound iodine, and total thyroxine were measured together with the T3 binding index. The daily excretion in the urine offree cortisol, 17-hydroxycorticoste- roids, 17-ketosteroids, pregnanediol, pregnanetriol, total oestrogens, total catecholamines, and 4-hydroxy-3-methoxymandelic acid was also assayed. The frequency distribution of the values obtained indicates that oral contraceptives have a marked influence on the endocrine environment. The smallest deviations were observed in urinary excretion of total catecholamines and of 4-hydroxy-3-methoxymandelic acid. In some individuals the hor- mone assays were continued throughout the menstrual cycle. The morning and afternoon levels of serum cortisol tended to increase during the period when the oral contraceptive was being taken. According to the estimates of the Advisory Com- to prescription, and had been doing so for at least mittee on Obstetrics and Gynecology (1969) of the 2 months. The types of oral contraceptive prepara- United States Food and Drug Administration, tions taken are shown in Table 1. 18.5 million women are using oral contraceptives. The urinary excretion of hormones and their The hormonal balance in these women may show metabolites was determined on 24-hour urine spe- deviations from that seen in normally menstruating cimens. The quantity of free cortisol in the urine was women and this problem was investigated in our assayed by the method of protein displacement bind- laboratory in order to establish the values for com- ing (Murphy, 1967) using newborn calf serum and monly used endocrine assays in women with spon- corticosterone-3H as reagents.
    [Show full text]
  • Pregnenolone Introduced 1997
    Product Information Sheet – September 2016 Pregnenolone Introduced 1997 What Is It? • This product should not be taken by individuals with healthy levels of pregnenolone. Pregnenolone, 3-alpha-hydroxy-5-beta-pregnen-20-one, is a precursor to over 150 steroid hormones and is produced naturally in • Pregnenolone is best utilized by individuals over 40, and should the body from cholesterol. not be used to enhance athletic ability or endurance. Uses For Pregnenolone Are There Any Precautions Or Potential Side Memory Support: Animal studies have reported that pregnenolone Effects? may help to enhance memory by modulating N-methyl-D-aspartate Precautions: (NMDA) and gamma aminobutyrate (GABA) receptor activity in the brain. One study suggested that pregnenolone helped promote • NOT FOR USE BY INDIVIDUALS UNDER THE AGE OF 18. post-training task learning and memory.* • DO NOT USE IF PREGNANT OR NURSING. Immune Health: One study indicated that the 7-hydroxy metabolites • KEEP OUT OF REACH OF CHILDREN. from pregnenolone may help promote healthy immune system • Consult a physician or licensed qualified health professional before response.* using this product if you have, or have a family history of breast Mood Support: Pregnenolone has been reported to help promote cancer, prostate cancer, prostate enlargement, heart disease, low feelings of emotional well-being. One study suggested that “good” cholesterol (HDL), or if you are using any other dietary pregnenolone supported positive mood and feelings of motivation supplement, prescription drug, or over-the-counter drug. by mediating dopamine release.* • Do not exceed the recommended serving. Exceeding the What Is The Source? recommended serving may cause serious adverse health effects.
    [Show full text]
  • Dietary Supplements Compendium Volume 1
    2015 Dietary Supplements Compendium DSC Volume 1 General Notices and Requirements USP–NF General Chapters USP–NF Dietary Supplement Monographs USP–NF Excipient Monographs FCC General Provisions FCC Monographs FCC Identity Standards FCC Appendices Reagents, Indicators, and Solutions Reference Tables DSC217M_DSCVol1_Title_2015-01_V3.indd 1 2/2/15 12:18 PM 2 Notice and Warning Concerning U.S. Patent or Trademark Rights The inclusion in the USP Dietary Supplements Compendium of a monograph on any dietary supplement in respect to which patent or trademark rights may exist shall not be deemed, and is not intended as, a grant of, or authority to exercise, any right or privilege protected by such patent or trademark. All such rights and privileges are vested in the patent or trademark owner, and no other person may exercise the same without express permission, authority, or license secured from such patent or trademark owner. Concerning Use of the USP Dietary Supplements Compendium Attention is called to the fact that USP Dietary Supplements Compendium text is fully copyrighted. Authors and others wishing to use portions of the text should request permission to do so from the Legal Department of the United States Pharmacopeial Convention. Copyright © 2015 The United States Pharmacopeial Convention ISBN: 978-1-936424-41-2 12601 Twinbrook Parkway, Rockville, MD 20852 All rights reserved. DSC Contents iii Contents USP Dietary Supplements Compendium Volume 1 Volume 2 Members . v. Preface . v Mission and Preface . 1 Dietary Supplements Admission Evaluations . 1. General Notices and Requirements . 9 USP Dietary Supplement Verification Program . .205 USP–NF General Chapters . 25 Dietary Supplements Regulatory USP–NF Dietary Supplement Monographs .
    [Show full text]
  • PDF Datasheet
    Product Datasheet Progesterone Antibody NB100-62847 Unit Size: 0.5 ml Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles. Protocols, Publications, Related Products, Reviews, Research Tools and Images at: www.novusbio.com/NB100-62847 Updated 5/17/2019 v.20.1 Earn rewards for product reviews and publications. Submit a publication at www.novusbio.com/publications Submit a review at www.novusbio.com/reviews/destination/NB100-62847 Page 1 of 2 v.20.1 Updated 5/17/2019 NB100-62847 Progesterone Antibody Product Information Unit Size 0.5 ml Concentration 5.0 mg/ml Storage Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles. Clonality Polyclonal Preservative 0.09% Sodium Azide Isotype IgG Purity Protein G purified Buffer PBS Product Description Host Rabbit Species All Species Reactivity Notes Broad Specificity/Sensitivity NB100-62847 is specific for progesterone, a steroid hormone synthesized from the cholesterol derivative, pregnenolone, in the cortex of the adrenal gland. Cross reactivity: 100% Progesterone 4% 11-deoxycoritcosterone 4% Corticosterone 3% 11 Hydroxyprogesterone 2.5% 20 Dihydroprogesterone 1.5% 17A Hydroxyprogesterone Less than 0.005% pregnanetriol, dihydrotestosterone, androstanedione, 11-deoxycortisol, 21 deoxycortisol, testostserone, 17b oestradiol, 17a oestradiol, dehydroepiandrosterone, androsterone, pregnanediol, pregnenolone, oestrone, oestriol, 16-Epi oestriol, and 6 keto oestradiol. Progesterone is secreted by the corpus luteum and acts to prepare the endometrium for the implantation of a fertilized egg. During pregnancy, it is secreted by the placenta in order to prevent spontaneous abortion and to stimulate the development of mammary tissue to produce milk.
    [Show full text]
  • Quantification of Hair Corticosterone, DHEA and Testosterone As
    animals Article Quantification of Hair Corticosterone, DHEA and Testosterone as a Potential Tool for Welfare Assessment in Male Laboratory Mice Alberto Elmi 1 , Viola Galligioni 2, Nadia Govoni 1 , Martina Bertocchi 1 , Camilla Aniballi 1 , Maria Laura Bacci 1 , José M. Sánchez-Morgado 2 and Domenico Ventrella 1,* 1 Department of Veterinary Medical Sciences, University of Bologna, 40064 Ozzano dell’Emilia, BO, Italy; [email protected] (A.E.); [email protected] (N.G.); [email protected] (M.B.); [email protected] (C.A.); [email protected] (M.L.B.) 2 Comparative Medicine Unit, Trinity College Dublin, D02 Dublin, Ireland; [email protected] (V.G.); [email protected] (J.M.S.-M.) * Correspondence: [email protected]; Tel.: +39-051-2097-926 Received: 11 November 2020; Accepted: 14 December 2020; Published: 16 December 2020 Simple Summary: Mice is the most used species in the biomedical research laboratory setting. Scientists are constantly striving to find new tools to assess their welfare, in order to ameliorate husbandry conditions, leading to a better life and scientific data. Steroid hormones can provide information regarding different behavioral tracts of laboratory animals but their quantification often require stressful sampling procedures. Hair represents a good, less invasive, alternative in such scenario and is also indicative of longer timespan due to hormones’ accumulation. The aim of the work was to quantify steroid hormones in the hair of male laboratory mice and to look for differences imputable to age and housing conditions (pairs VS groups). Age influenced all analysed hormones by increasing testosterone and dehydroepiandrosterone (DHEA) levels and decreasing corticosterone.
    [Show full text]